ZD 0473

We present the method of theoretical calculations of the Raman intensities and the simulated Raman spectra of platinum(II… (More)

Purpose: ZD0473 (AMD473) [cis-amminedichloro(2-methylpyridine) platinum(II)] is a novel platinum agent of proven activity in… (More)

ZD0473 is a new generation platinum agent that, in preclinical studies, shows evidence of an extended spectrum of anti-tumor… (More)

A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural… (More)

ZD0473 is a new generation hindered platinum agent currently undergoing worldwide Phase II clinical studies. The in vitro… (More)

The primary aim of this phase II trial was to assess the antitumour activity of ZD0473 in ovarian cancer patients who had failed… (More)

Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as a determinant of cisplatin… (More)

Acquired drug resistance to the sterically hindered platinum drug ZD0473 (formerly known as JM473 and AMD473) and currently being… (More)

ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey… (More)

Platinum drugs play an important role in the treatment of cancer, but there is room for improvement. Here we present a new… (More)